NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Abu‐Rustum, Nadeem R.; Yashar, Catheryn M.; Bean, Sarah; Bradley, Kristin; Campos, Susana M.; Chon, Hye Sook; Chu, Christina; Cohn, David E.; Crispens, Marta A.; Damast, Shari; Fisher, Christine M.; Frederick, Peter J.; Gaffney, David K.; Giuntoli, Robert L.; Han, Ernest; Huh, Warner K.; Lurain, John R.; Mariani, Andrea; Mutch, David G.; Nagel, Christa; Nekhlyudov, Larissa; Fader, Amanda N.; Remmenga, Steven W.; Reynolds, R. Kevin; Sisodia, Rachel; Tillmanns, Todd; Ueda, Stefanie; Urban, Renata R.; Wyse, Emily; McMillian, Nicole R.; Motter, Angela D.

doi:10.6004/jnccn.2020.0027

Cited by 247 publications

(252 citation statements)

References 21 publications

Supporting

Mentioning

217

Contrasting

Unclassified

Order By: Relevance

“…There is also a lack of consensus in the use of RT which is reflected in the NCCN guidelines with lists VBT and/or EBRT as an option for those with grade 1–2 tumors and EBRT with/without VBT with/without systemic therapy [ 26 ]. Furthermore, the NCCN guidelines also state that surveillance may be appropriate for patients undergoing radical hysterectomy with negative surgical margins.…”

Section: Discussionmentioning

confidence: 99%

Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study

2020

View full text Add to dashboard Cite

Objective The management of stage II endometrial cancer (EC) is challenging due to the wide variation in surgical practice and adjuvant treatment recommendations. We sought to describe the treatment patterns for patients with stage II EC and to evaluate the association between surgical management and adjuvant therapy on survival outcomes in a large cohort of patients with stage II EC. Methods Using data from the National Cancer Database, we identified 9,690 women with stage II EC. We used logistic regression to identify association of sociodemographic and tumor characteristics with surgery type and receipt of adjuvant therapy. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for associations between adjuvant therapy, hysterectomy type, and overall survival. Results Almost 11% of the cohort underwent radical hysterectomy; however, there was no difference in survival between surgical types even when adjusted for adjuvant therapy (HR=0.94; 95% CI=0.82–1.07). Compared to no adjuvant treatment, radiation only (HR=0.66; 95% CI=0.61–0.73) and combination radiation and chemotherapy (HR=0.53; 95% CI=0.45–0.62) were associated with lower risk of death. There was no survival benefit of chemotherapy alone even when separated by histologic subtype (HR range, 0.55–1.46). Conclusions Women with stage II EC do not appear to benefit from routine radical hysterectomy though all patients appear to benefit from receipt of radiation therapy (RT), regardless of modality. Additionally, there may be an added survival benefit with the combination of computed tomography and RT in patients with non-endometrioid, high-risk histologies.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study

2020

View full text Add to dashboard Cite

show abstract

“…Guidelines from the NCCN (version 1.2020) recommend radiation therapy forms the basis of treatment of patients with CC. 25 Radioresistance is one of the most important reasons for the failure or ineffectiveness of CC radiation therapy. 26,27 Previous studies have found that the abnormal expression of LncRNAs has an important effect on the radioresistance of cancer.…”

Section: Discussionmentioning

confidence: 99%

<p>Knockdown of lncRNA PCAT1 Enhances Radiosensitivity of Cervical Cancer by Regulating miR-128/GOLM1 Axis</p>

et al. 2020

OTT

View full text Add to dashboard Cite

Purpose: Cervical cancer (CC) is the fourth most common cancer with high death rate in females. The study aims to detect the mechanism of long non-coding RNA (LncRNA) PCAT1 on radiosensitivity of CC. Methods: The expression of PCAT1, miR-128 and GOLM1 in CC tissues and cells was measured by qRT-PCR. Different doses of X-ray were used for radiation treatment of CC cells and 6 Gy was chosen to perform the following experiments. The proliferation, migration and invasion of CC cells were measured by MTT assay, wound healing assay and transwell assay, respectively. The target relationships among PCAT1, miR-128 and GOLM1 were predicted by StarBase and TargetScan and verified by luciferase reporter assay. The protein level of GOLM1 was determined by Western blot. The xenograft tumor model was constructed in nude mice to verify the effect of PCAT1 on radiosensitivity of CC in vivo. Results: The PCAT1 expression was upregulated in CC tissues and cells. PCAT1 silencing enhances radiosensitivity of CC cells on proliferation, migration and invasion. MiR-128 was the target of PCAT1 and was negatively regulated by PCAT1. Upregulation of miR-128 enhances radiosensitivity of CC cells on proliferation, migration and invasion. GOLM1 was a target of miR-128 and was negatively regulated by miR-128. Upregulation of GOLM1 and downregulation of miR-128 both reversed the enhanced effect of PCAT1 knockdown on radiosensitivity of CC cells, which partly promoted the proliferation, migration and invasion of CC cells. Conclusion: Silencing of PCAT1 enhanced radiosensitivity of CC via targeting miR-128/ GOLM1, which provided a new idea for treating CC.

show abstract

“…The standard treatment for locally advanced carcinoma cervix (LACC) as per National Comprehensive Cancer Network (NCCN) guidelines is concurrent chemoradiation therapy, which further depends on the status of par-aortic lymph nodes involvement [13]. For patients without adenopathy, the standard treatment is radiation therapy (RT) with concurrent platinum-containing chemotherapy along with brachytherapy.…”

Section: Standard Treatment For Locally Advanced Carcinoma Cervix (Stmentioning

confidence: 99%

“…For patients without adenopathy, the standard treatment is radiation therapy (RT) with concurrent platinum-containing chemotherapy along with brachytherapy. The patients with para-aortic lymphadenopathy, the RT is provided to the involved nodes [13].…”

Section: Standard Treatment For Locally Advanced Carcinoma Cervix (Stmentioning

confidence: 99%

See 1 more Smart Citation

Redefining Role of 5-Fluorouracil and Exploring the Impact of Taxanes and Cisplatin in Locally Advanced and Recurrent Carcinoma Cervix in Concurrent Setting With Radiotherapy: A Literature Review

Kaur

Marcus

Garg

et al. 2020

Cureus

View full text Add to dashboard Cite

Cervical carcinoma is the fourth most frequent cancer among women worldwide while it is common in rural India. The irony of the situation is that it continues to present in a locally advanced stage with bulky disease posing a significant challenge to the current treatment modalities despite various screening programs. Concurrent chemoradiotherapy is the mainstay of treatment for locally advanced carcinoma cervix. However, the appropriate dosing schedules, along with the salutation of the chemotherapeutic agent, remain a matter of debate to date. The use of chemotherapy in the neoadjuvant and adjuvant setting promises to improve progression-free survival and overall survival. The article aims to review various chemotherapy and their regimens in the treatment of carcinoma of the cervix.

show abstract

NCCN Guidelines Insights: Cervical Cancer, Version 1.2020

Cited by 247 publications

References 21 publications

Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study

Management of stage II endometrial cancer and subsequent oncologic outcomes: a National Cancer Database study

<p>Knockdown of lncRNA PCAT1 Enhances Radiosensitivity of Cervical Cancer by Regulating miR-128/GOLM1 Axis</p>

Redefining Role of 5-Fluorouracil and Exploring the Impact of Taxanes and Cisplatin in Locally Advanced and Recurrent Carcinoma Cervix in Concurrent Setting With Radiotherapy: A Literature Review

Contact Info

Product

Resources

About